이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

eFFECTOR Therapeutics 관리

관리 기준 확인 0/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Craig Jalbert

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	n/a
경영진 평균 재임 기간	1.9yrs
이사회 평균 재임 기간	2.9yrs

최근 관리 업데이트

Recent updates

eFFECTOR doses first patient in second cohort of phase 1b trial of potential COVID drug

Sep 14

eFFECTOR Therapeutics GAAP EPS of -$0.17

Aug 09

eFFECTOR: Developing New Class Of Cancer Therapies

Sep 12

CEO

Craig Jalbert (62 yo)

less than a year

테뉴어

Mr. Craig R. Jalbert, CIRA, serves as President, CEO, Treasurer, Secretary and Director of eFFECTOR Therapeutics, Inc. since June 2024. He serves as President, Corporate Secretary, Principal Executive Offi...

리더십 팀

이름	위치	테뉴어	보상	소유권
Michael Byrnes	Chief Financial Officer	3.6yrs	US$826.59k	0.066% $ 832.0
Douglas Warner	Chief Medical Officer	1.9yrs	US$746.04k	0% $ 0
Craig Jalbert	CEO, President	less than a year	데이터 없음	데이터 없음
Davide Ruggero	Co-Founder and Member of Clinical & Scientific Advisory Board	no data	데이터 없음	데이터 없음
Kevan Shokat	Co-Founder and Member of Clinical & Scientific Advisory Board	no data	데이터 없음	데이터 없음

1.9yrs

평균 재임 기간

52yo

평균 연령

경험이 풍부한 관리: EFTR 의 관리팀은 경험 (평균 재직 기간 1.8 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Craig Jalbert	CEO, President	less than a year	데이터 없음	데이터 없음
Davide Ruggero	Co-Founder and Member of Clinical & Scientific Advisory Board	no data	데이터 없음	데이터 없음
Kevan Shokat	Co-Founder and Member of Clinical & Scientific Advisory Board	no data	데이터 없음	데이터 없음
Christopher Ehrlich	Independent Director	2.9yrs	US$80.92k	0.15% $ 1.9k
Neal Rosen	Member of Clinical & Scientific Advisory Board	no data	데이터 없음	데이터 없음
Caroline Loewy	Independent Director	less than a year	US$35.70k	0.0077% $ 96.3
Joan Brugge	Member of Clinical & Scientific Advisory Board	no data	데이터 없음	데이터 없음
Jennifer Doudna	Member of Clinical & Scientific Advisory Board	no data	데이터 없음	데이터 없음
Kapil Dhingra	Member of Clinical & Scientific Advisory Board	no data	데이터 없음	데이터 없음
Brian Gallagher	Independent Chairman	4.5yrs	US$109.82k	0.026% $ 320.3
Elizabeth Bhatt	Independent Director	3.5yrs	US$73.48k	0.0077% $ 96.3
Funda Meric-Bernstam	Member of Clinical & Scientific Advisory Board	no data	데이터 없음	데이터 없음

2.9yrs

평균 재임 기간

58.5yo

평균 연령

경험이 풍부한 이사회: EFTR 의 이사회는 경험(평균 재직 기간 2.8 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

eFFECTOR Therapeutics 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

eFFECTOR Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

eFFECTOR Therapeutics, Inc. Appoints Caroline Loewy to its Board of Directors

eFFECTOR Therapeutics, Inc., Annual General Meeting, Jun 22, 2023

High number of new directors

Effector Therapeutics Appoints Mayank Gandhi, M.D., as Chief Business Officer

eFFECTOR Therapeutics Appoints Douglas Warner as Chief Medical Officer

Recent updates

eFFECTOR Therapeutics Provides Non-Compliance Update

eFFECTOR Therapeutics Plans to Voluntarily Request a Delisting of its Securities and Expects its Securities to be Delisted in the Near Term

eFFECTOR Therapeutics, Inc. Receives Written Notice from Nasdaq Regarding Minimum Value of Listed Securities

New major risk - Revenue and earnings growth

eFFECTOR Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

eFFECTOR Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

New major risk - Market cap size

New major risk - Share price stability

eFFECTOR Therapeutics, Inc. Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer

Price target decreased by 92% to US$22.50

New major risk - Share price stability

eFFECTOR Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $15.000003 million.

Price target increased by 90% to US$275

eFFECTOR Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $15.000003 million.

eFFECTOR Therapeutics, Inc. Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in Er+ Metastatic Breast Cancer Patients

eFFECTOR Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of Er+/Her2- Advanced Metastatic Breast Cancer

New major risk - Shareholder dilution

Third quarter 2023 earnings released: US$0.13 loss per share (vs US$0.23 loss in 3Q 2022)

Effector Therapeutics, Inc. Announces Initiation of Dosing in an Investigator-Initiated Phase 1 Dose Escalation Trial Evaluating Tomivosertib in Patients with Relapsed/Refractory Acute Myeloid Leukemia (Aml)

eFFECTOR Therapeutics, Inc. Appoints Caroline Loewy to its Board of Directors

Price target decreased by 11% to US$6.58

eFFECTOR Therapeutics Receives Non-Compliance Notice from Nasdaq Stock Market Regarding Non-Compliance with Nasdaq's Minimum Bid Price Requirement

eFFECTOR Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $8.733186 million.

eFFECTOR Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $7.49325 million.

eFFECTOR Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $7.49325 million.

Price target increased by 17% to US$7.38

eFFECTOR Therapeutics Receives Non-Compliance Notice from Nasdaq

eFFECTOR Therapeutics, Inc., Annual General Meeting, Jun 22, 2023

Price target increased by 16% to US$6.33

eFFECTOR Therapeutics, Inc. Provides Positive Clinical Data Update for Zotatifin and General Corporate Update

Price target decreased to US$8.60

Price target increased to US$10.75

High number of new directors

Effector Therapeutics Completes Enrollment in Second of Three Cohorts of Phase 1B Clinical Trial of Zotatifin for the Treatment of Covid-19

Effector Therapeutics Appoints Mayank Gandhi, M.D., as Chief Business Officer

eFFECTOR Therapeutics, Inc. Doses First Patient in Second Cohort of Phase 1B Clinical Trial of Zotatifin for the Treatment of Covid-19

eFFECTOR doses first patient in second cohort of phase 1b trial of potential COVID drug

eFFECTOR Therapeutics Receives A Letter from the Nasdaq Stock Market Staff

Consensus forecasts updated

Price target decreased to US$10.68

eFFECTOR Therapeutics GAAP EPS of -$0.17

eFFECTOR Therapeutics Appoints Douglas Warner as Chief Medical Officer

eFFECTOR Therapeutics, Inc. Announces Executive Changes

Investor sentiment deteriorated over the past week

eFFECTOR Therapeutics, Inc. Reports Positive Interim Results in Zotatifin (eFT226) Phase 1/2 Clinical Trial at ASCO 2022 Showing Safety and Tolerability, and Initial Signals of Clinical Activity

Investor sentiment improved over the past week

eFFECTOR Therapeutics, Inc. Announces Interim Data from Its Ongoing Phase 1/2 Clinical Trial of Zotatifin in Solid Tumors

Consensus forecasts updated

Investor sentiment deteriorated over the past week

High number of new directors

eFFECTOR Therapeutics, Inc., Annual General Meeting, Jun 09, 2022

eFFECTOR Therapeutics, Inc. Announces Transition in Clinical Leadership

Consensus forecasts updated

Investor sentiment improved over the past week

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

eFFECTOR Therapeutics, Inc. Announces Directorate Changes

eFFECTOR Therapeutics, Inc. Provides Pipeline and Business Updates

High number of new directors

Independent Director recently sold US$475k worth of stock

eFFECTOR Therapeutics, Inc. Announces Publication of Zotatifin Preclinical Data in Frontiers in Oncology

Independent Director recently sold US$407k worth of stock

Independent Director recently sold US$222k worth of stock

Independent Director recently sold US$917k worth of stock

Third quarter 2021 earnings released: EPS US$0.53

eFFECTOR: Developing New Class Of Cancer Therapies

CEO

테뉴어

리더십 팀

평균 재임 기간